Pancreatic Cancer Research

ResearcherUniversità Campus Bio-MedicoActive in the last 2 years

Daniele Santini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-9118-3337; OpenAlex author ID A5091765229. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 10

  1. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Co-author DOI 10.1002/cam4.7345↗
  2. The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets. Co-author DOI 10.3389/fonc.2023.1154581↗
  3. Prognostic and predictive factors in pancreatic cancer. Last author DOI 10.18632/oncotarget.27518↗
  4. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? Co-author DOI 10.1016/j.critrevonc.2017.03.025↗
  5. Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.critrevonc.2015.11.016↗
  6. hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/bjc.2015.28↗
  7. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Co-author DOI 10.18632/oncotarget.4492↗
  8. Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. The beginning of a new era? Case report and review of the literature. Co-author DOI 10.1016/j.pan.2014.07.002↗
  9. Germline copy number variation in the YTHDC2 gene: does it have a role in finding a novel potential molecular target involved in pancreatic adenocarcinoma susc… Co-author DOI 10.1517/14728222.2014.920324↗
  10. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Co-author DOI 10.3390/ijms141019731↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Davide Melisi · 2 shared papers, 2017–2024 · strength 0.21
  2. Michela Roberto · 1 shared paper, 2023 · strength 0.18
  3. Paolo Marchetti · 1 shared paper, 2023 · strength 0.18
  4. Federica Tomao · 1 shared paper, 2023 · strength 0.18
  5. Nicola Silvestris · 4 shared papers, 2013–2017 · strength 0.18
  6. Emanuela Dell’Aquila · 2 shared papers, 2017–2020 · strength 0.16
  7. Oronzo Brunetti · 3 shared papers, 2015–2017 · strength 0.15
  8. Vanja Vaccaro · 1 shared paper, 2024 · strength 0.15
  9. Letizia Procaccio · 1 shared paper, 2024 · strength 0.15
  10. Elisa Giommoni · 1 shared paper, 2024 · strength 0.15
  11. Sara Lonardi · 1 shared paper, 2024 · strength 0.15
  12. Ferdinando De Vita · 1 shared paper, 2024 · strength 0.15
  13. Vincenzo Ricci · 1 shared paper, 2024 · strength 0.15
  14. Francesca Bergamo · 1 shared paper, 2024 · strength 0.15
  15. Guido Giordano · 1 shared paper, 2024 · strength 0.15
  16. Matteo Landriscina · 1 shared paper, 2024 · strength 0.15
  17. Giovanni Lo Re · 1 shared paper, 2024 · strength 0.15
  18. Roberto Bianco · 1 shared paper, 2024 · strength 0.15
  19. Giampaolo Tortora · 1 shared paper, 2024 · strength 0.15
  20. Michèle Milella · 1 shared paper, 2024 · strength 0.15
  21. Enrico Vasile · 1 shared paper, 2024 · strength 0.15
  22. Alberto Zaniboni · 1 shared paper, 2024 · strength 0.15
  23. Aldo Scarpa Scarpa · 3 shared papers, 2013–2016 · strength 0.12
  24. Giuseppe Aprile · 2 shared papers, 2015–2017 · strength 0.10
  25. Bruno Vincenzi · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.